AU2020222239B2 - Car T-cells for the treatment of CD1a-positive cancer - Google Patents

Car T-cells for the treatment of CD1a-positive cancer Download PDF

Info

Publication number
AU2020222239B2
AU2020222239B2 AU2020222239A AU2020222239A AU2020222239B2 AU 2020222239 B2 AU2020222239 B2 AU 2020222239B2 AU 2020222239 A AU2020222239 A AU 2020222239A AU 2020222239 A AU2020222239 A AU 2020222239A AU 2020222239 B2 AU2020222239 B2 AU 2020222239B2
Authority
AU
Australia
Prior art keywords
cd1a
carts
cells
cdla
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020222239A
Other languages
English (en)
Other versions
AU2020222239A1 (en
Inventor
Clara Bueno Uroz
Francisco GUTIÉRREZ AGÜERA
Pablo MENÉNDEZ BUJÁN
Heleia ROCA-HO
Diego SANCHEZ MARTÍNEZ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institucio Catalana de Recerca i Estudis Avancats ICREA
Fundacio Institut dInvestigacio en Ciencies de la Salut Germans Trias i Pujol IGTP
Fundacio Institut de Recerca contra la Leucemia Josep Carreras
Original Assignee
Institucio Catalana de Recerca i Estudis Avancats ICREA
Fundacio Institut dInvestigacio en Ciencies de la Salut Germans Trias i Pujol IGTP
Fundacio Institut de Recerca contra la Leucemia Josep Carreras
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institucio Catalana de Recerca i Estudis Avancats ICREA, Fundacio Institut dInvestigacio en Ciencies de la Salut Germans Trias i Pujol IGTP, Fundacio Institut de Recerca contra la Leucemia Josep Carreras filed Critical Institucio Catalana de Recerca i Estudis Avancats ICREA
Publication of AU2020222239A1 publication Critical patent/AU2020222239A1/en
Application granted granted Critical
Publication of AU2020222239B2 publication Critical patent/AU2020222239B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4213—CD74, Ii, MHC class II invariant chain or MHC class II gamma chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4224—Molecules with a "CD" designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2020222239A 2019-02-14 2020-02-13 Car T-cells for the treatment of CD1a-positive cancer Active AU2020222239B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19382104.8 2019-02-14
EP19382104.8A EP3696191A1 (en) 2019-02-14 2019-02-14 Car t-cells for the treatment of cd1a-positive cancer
PCT/EP2020/053769 WO2020165350A1 (en) 2019-02-14 2020-02-13 Car t-cells for the treatment of cd1a-positive cancer

Publications (2)

Publication Number Publication Date
AU2020222239A1 AU2020222239A1 (en) 2021-10-07
AU2020222239B2 true AU2020222239B2 (en) 2024-12-05

Family

ID=65685281

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020222239A Active AU2020222239B2 (en) 2019-02-14 2020-02-13 Car T-cells for the treatment of CD1a-positive cancer

Country Status (8)

Country Link
US (1) US12215158B2 (https=)
EP (2) EP3696191A1 (https=)
JP (2) JP7590737B2 (https=)
CN (2) CN118436770A (https=)
AU (1) AU2020222239B2 (https=)
CA (1) CA3128955A1 (https=)
MX (1) MX2021009798A (https=)
WO (1) WO2020165350A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3696191A1 (en) * 2019-02-14 2020-08-19 Fundación Instituto de Investigación contra la Leucemia Josep Carreras (IJC) Car t-cells for the treatment of cd1a-positive cancer
US11746154B2 (en) 2020-10-09 2023-09-05 Pfizer Inc. CD1a antibodies and uses thereof
AU2022282828A1 (en) * 2021-05-26 2023-12-14 Oxford University Innovation Limited Antibodies
IT202100027929A1 (it) * 2021-11-02 2023-05-02 Univ Degli Studi Magna Graecia Di Catanzaro Un nuovo anticorpo bispecifico asimmetrico(UMG2/CD1a-CD3e) per il trattamento immunologico della forma corticale di leucemia linfoblastica acuta T (T-ALL) pediatrica e dell’adulto
EP4234582A1 (en) * 2022-02-28 2023-08-30 Onechain Immunotherapeutics SL Humanized cd1a targeting moiety for the treatment of cd1a-positive cancer
CA3251493A1 (en) * 2022-02-28 2023-08-31 Onechain Immunotherapeutics S.L Humanized CD1A Targeting Fraction for Treating CD1A-Positive Cancer
GB202217923D0 (en) * 2022-11-29 2023-01-11 Univ Oxford Innovation Ltd Antibodies
EP4417623A1 (en) * 2023-02-15 2024-08-21 Fundació Institut de Recerca Contra la Leucèmia Josep Carreras Ccr9 targeting moiety for the treatment of ccr9-positive cancer
EP4545085A1 (en) * 2023-10-26 2025-04-30 Fundación Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz Car t-cells against cd79b for the treatment of non-hodgkin lymphoma
CN119685260B (zh) * 2024-12-17 2026-01-13 上海交通大学医学院附属瑞金医院 一种具有新型穿膜区的嵌合抗原受体t细胞及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0436597B1 (en) 1988-09-02 1997-04-02 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
EP0585287B1 (en) 1990-07-10 1999-10-13 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
CA2405246A1 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with alterred binding properties
EP0575485A1 (en) 1991-03-01 1993-12-29 Dyax Corp. Process for the development of binding mini-proteins
DK0580737T3 (da) 1991-04-10 2004-11-01 Scripps Research Inst Heterodimere receptorbiblioteker ved anvendelse af phagemider
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
GB0717101D0 (en) * 2007-09-03 2007-10-10 Cambridge Entpr Ltd Tumour marker
AU2015327868A1 (en) 2014-10-03 2017-04-20 Novartis Ag Combination therapies
CN107708741A (zh) * 2015-06-12 2018-02-16 免疫医疗公司 用嵌合抗原受体(car)构建体和表达car构建体的t细胞(car‑t)或nk细胞(car‑nk)进行的疾病疗法
EP3696191A1 (en) * 2019-02-14 2020-08-19 Fundación Instituto de Investigación contra la Leucemia Josep Carreras (IJC) Car t-cells for the treatment of cd1a-positive cancer

Also Published As

Publication number Publication date
JP2022520455A (ja) 2022-03-30
US12215158B2 (en) 2025-02-04
MX2021009798A (es) 2021-11-17
AU2020222239A1 (en) 2021-10-07
JP2025024031A (ja) 2025-02-19
EP3696191A1 (en) 2020-08-19
CN113795506A (zh) 2021-12-14
CN118436770A (zh) 2024-08-06
EP3924374A1 (en) 2021-12-22
CA3128955A1 (en) 2020-08-20
US20220143085A1 (en) 2022-05-12
JP7590737B2 (ja) 2024-11-27
WO2020165350A1 (en) 2020-08-20

Similar Documents

Publication Publication Date Title
AU2020222239B2 (en) Car T-cells for the treatment of CD1a-positive cancer
AU2021203790B2 (en) Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
AU2017302668A1 (en) Combination therapies of chimeric antigen receptors and PD-1 inhibitors
EP3423482A1 (en) Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore
JP7729561B2 (ja) 多発性骨髄腫治療用の抗ｂｃｍａ ｃａｒ ｔ細胞
JP7545139B2 (ja) Ｂ細胞急性リンパ芽球性白血病（ｂ－ａｌｌ）の処置のためのｃｄ２２標的化部分
US20260116982A1 (en) Car t-cells for the treatment of cd1a-positive cancer
HK40116152A (zh) 用於治疗cd1a阳性癌症的car t细胞
EP4417623A1 (en) Ccr9 targeting moiety for the treatment of ccr9-positive cancer
WO2025171124A1 (en) Methods of treating prostate cancer with bispecific anti-psma x anti-cd3 antibodies and bispecific anti-psma x anti-cd28 antibodies
WO2025109223A1 (en) Cd7 targeting moieties for the treatment of cd7 positive cancer

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)